Combination GLP-1 and SGLT2 therapy may provide additive benefits in type 2 diabetes

PHILADELPHIA — Using a GLP-1 receptor agonist in combination with an SGLT2 inhibitor may provide additive cardiovascular and renal benefits for people with type 2 diabetes, according to a speaker at the Heart in Diabetes CME Conference. Silvio E. Inzucchi, MD, medical director at the Yale Diabetes Center and a Healio | Endocrine Today Editorial Board Member, said there will likely never be